ProQR Therapeutics N.V. PRQR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 26.56% | -47.63% | -4.69% | -44.35% | -377.04% |
| Total Depreciation and Amortization | 7.34% | 13.81% | 10.50% | 3.71% | 0.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.40% | 392.38% | 947.39% | 93.26% | 298.41% |
| Change in Net Operating Assets | -400.59% | 101.80% | -1,195.84% | -392.66% | 73.08% |
| Cash from Operations | -10.29% | 21.57% | -56.04% | -130.00% | -92.16% |
| Capital Expenditure | -195.38% | 18.58% | -331.81% | 37.15% | 60.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -195.38% | 18.58% | 79.40% | -101.08% | 60.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -111.95% | 46.38% | -137.55% | 2.20% | 0.34% |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 17,093.20% | 32.40% | -100.92% | -4.24% | -9.56% |
| Foreign Exchange rate Adjustments | 102.16% | 167.85% | -98.16% | 79.07% | -1,553.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 391.97% | 25.91% | -126.33% | -231.33% | -97.80% |